WATCH NOW: ALPROLIX® was the first EHL factor IX product approved for use in hemophilia B1
Since its approval in 20142*:
More than 1300 patients
have been prescribed
ALPROLIX†
More than 800 million units
of ALPROLIX have
been shipped across the country‡
Hear from real patients taking ALPROLIX
Meet Casey
An adult male with severe hemophilia B.
The flexibility of ALPROLIX means Casey could find a dosing interval that worked for him.
After starting on an every-10-day dosing schedule, I talked with my doctor and was able to adjust my dosing interval.
Meet Alex
A youth soccer coach with moderate hemophilia B.
Alex was able to extend his dosing interval with ALPROLIX.
After working with my doctor and starting on an every-10-day dosing regimen, I was able to extend my dosing interval and infuse beyond every 14 days.
Meet Brian
A father and hiker with severe hemophilia B.
Brian transitioned from on demand to prophylaxis with ALPROLIX.
When I was a teenager, I thought that skipping infusions gave me more control over my hemophilia. I was wrong...my hematologist told me about ALPROLIX and a starting interval of once a week or every 10 days. I was really excited about that.
Patient stories reflect the real-life experiences of persons diagnosed with hemophilia who have been prescribed ALPROLIX. However, individual experiences may vary. Patient stories are not necessarily representative of what another person using ALPROLIX may experience. Patients have been compensated for sharing their stories.
*The FDA approval date for ALPROLIX was March 28, 2014.
†Based on specialty pharmacy dispensing records, specialty pharmacy distributor shipment records, third-party logistics’ shipment records, and internal retention estimates from May 2014 through June 2020.2
‡Units include those that have been shipped to patients from May 2014 through January 2020 and do not include inventory at specialty pharmacy providers or specialty distributors.2
EHL=extended half-life.
